Literature DB >> 9143240

Enhancement of EAE and induction of autoantibodies to T-cell epitopes in mice infected with a recombinant vaccinia virus encoding myelin proteolipid protein.

L Y Wang1, R S Fujinami.   

Abstract

SJL/J mice were infected with a recombinant vaccinia virus encoding myelin proteolipid protein (PLP) (VVplp). Antibody responses to whole PLP and to encephalitogenic peptides, p139-151, p178-191 or p104-117 were measured after vaccination and following challenge with these three PLP peptides. Competitive ELISAs showed that antibodies to p139-151 and p178-191 represented the majority of antibodies in the anti-PLP antibody response following VVplp vaccination, since the antibodies to intact PLP could be inhibited 56, 35 and 1%, respectively, by p139-151, p178-191 and p104-117. After peptide challenge, epitope specific anti-peptide antibodies were enhanced. These anti-peptide antibodies also reacted with the intact PLP molecule. Interestingly, the mean titer of anti-p139-151 antibody in p139-151 challenged mice was significantly higher than that observed for anti-p178-191 in p178-191 and for anti-p104-117 in p104-117 challenged mice. Following peptide challenge, the anti-PLP IgG response shifted from an IgG1 to an IgG2a and 2b phenotype. In these mice, both the clinical disease and histological pattern of experimental allergic encephalomyelitis (EAE) were enhanced. The enhancement was most pronounced in the pathologic scores in the p139-151 challenged group followed by p104-117 challenged mice. Thus, humoral immune responses to PLP encephalitogenic peptides can be generated with virus encoding a self central nervous system (CNS) protein.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143240     DOI: 10.1016/s0165-5728(96)00235-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  13 in total

Review 1.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

Review 2.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Polyreactive myelin oligodendrocyte glycoprotein antibodies: Implications for systemic autoimmunity in progressive experimental autoimmune encephalomyelitis.

Authors:  Lisa K Peterson; Ikuo Tsunoda; Takahisa Masaki; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2007-01-02       Impact factor: 3.478

Review 4.  Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Vaccine       Date:  2010-09-16       Impact factor: 3.641

Review 5.  The potential role of B cell-targeted therapies in multiple sclerosis.

Authors:  Aaron Boster; Daniel P Ankeny; Michael K Racke
Journal:  Drugs       Date:  2010-12-24       Impact factor: 9.546

Review 6.  Studies in the modulation of experimental autoimmune encephalomyelitis.

Authors:  Jane E Libbey; Ikuo Tsunoda; Robert S Fujinami
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-17       Impact factor: 4.147

7.  Bioinformatics Analysis of Gut Microbiota and CNS Transcriptome in Virus-Induced Acute Myelitis and Chronic Inflammatory Demyelination; Potential Association of Distinct Bacteria With CNS IgA Upregulation.

Authors:  Seiichi Omura; Fumitaka Sato; Ah-Mee Park; Mitsugu Fujita; Sundar Khadka; Yumina Nakamura; Aoshi Katsuki; Kazuto Nishio; Felicity N E Gavins; Ikuo Tsunoda
Journal:  Front Immunol       Date:  2020-07-07       Impact factor: 7.561

Review 8.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis.

Authors:  Diethilde J Theil; Jane E Libbey; Fernando Rodriguez; J Lindsay Whitton; Ikuo Tsunoda; Tobias J Derfuss; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2008-11-15       Impact factor: 3.478

Review 10.  Potential triggers of MS.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Results Probl Cell Differ       Date:  2010
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.